What's breaking now, across thousands of outlets.
The business of advancing shelved pharma assets continues to reap benefits, this time for Beeline Medicines and a lupus candidate provided by Bristol Myers Squibb. The buzzy Bain-backed startup said Wednesday that its drug afimetoran ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Tyra Biosciences wants to challenge Johnson & Johnson in a low-risk form of bladder cancer. The Phase 2 data it released Wednesday takes a step toward that goal — although you just might have to…
A new blood-based screening algorithm dramatically reduced the number of unnecessary PET scans needed to recruit patients at risk of Alzheimer's disease for a clinical trial, according to research…
Reminiscing about a past romantic partner might seem like a bad idea for your current love life. A new psychology study reveals that experiencing nostalgia for an ex can actually boost satisfaction in…
Kura Oncology, the maker of the leukemia menin inhibitor Komzifti, is spinning out its diabetes R&D to a new company that has attracted the attention of the leading pharma in the metabolic ...
Pfizer and Merck KGaA's venture groups are backing a nimble cancer startup taking a different approach to the popular antibody-drug conjugate and radioligand fields.
After tinkering with the biology of the broadly appealing anti-inflammatory NLRP3 pathway, NodThera is now plotting its pivotal trial plans for 2027.
